Co-Occurring EGFR S645C and EGFR L858R in a Patient with Lung Adenocarcinoma Induced Primary Resistance to Osimertinib-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Co-Occurring EGFR S645C and EGFR L858R in a Patient with Lung Adenocarcinoma Induced Primary Resistance to Osimertinib

Published:2023-10 Issue: Volume:Volume 14 Page:79-84
ISSN:1179-2728
Container-title:Lung Cancer: Targets and Therapy
language:en
Short-container-title:LCTT

Author:

Wang Li,Quan Fei^ORCID,Guo Zhen,Lu Zhongyu,Yang Duoxia,Shi Meiqi^ORCID

Publisher

Informa UK Limited

Subject

Oncology

Reference18 articles.

1. A Prospective, Molecular Epidemiology Study of EGFR Mutations in Asian Patients with Advanced Non–Small-Cell Lung Cancer of Adenocarcinoma Histology (PIONEER)

2. Pan-cancer clinical impact of latent drivers from double mutations

3. The in cis compound EGFR mutations in Chinese advanced non-small cell lung cancer patients

4. Clinical features and therapeutic options in non‐small cell lung cancer patients with concomitant mutations of EGFR , ALK , ROS1 , KRAS or BRAF

5. Targeting EGFR and VEGF(R) pathway cross-talk in tumor survival and angiogenesis

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Afatinib Plus Bevacizumab Treatment for a Patient With EGFR S645C–Mutant Non–Small Cell Lung Cancer: A Case Report;JCO Precision Oncology;2024-06

2. A graphSAGE discovers synergistic combinations of Gefitinib, paclitaxel, and Icotinib for Lung adenocarcinoma management by targeting human genes and proteins: the RAIN protocol;2024-04-16

3. Multiple drugs;Reactions Weekly;2024-01-13

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3